Age-related macular degeneration therapeutic - Biophytis

Drug Profile

Age-related macular degeneration therapeutic - Biophytis

Alternative Names: BIO 201; MACUNEOS

Latest Information Update: 01 Jul 2016

Price : $50

At a glance

  • Originator Biophytis
  • Class
  • Mechanism of Action Peroxisome proliferator-activated receptor alpha agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Clinical Phase Unknown Age-related macular degeneration

Most Recent Events

  • 01 Jul 2016 Clinical trials in Age-related macular degeneration (In volunteers, In the elderly) in France (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top